Vaxart, Inc. (VXRT) stock was climbing in the intraday session today after Vaxart stock announced positive results of its oral vaccine platform. VXRT stock price saw a surge of 9.14% to reach $8.96 a share at the time of this writing. The stock was 2.24% above at the previous closing. Let’s explore more of it.
Vaxart stock’s vaccine showed boosted immune response:
It is right to say that the VXRT oral tablet vaccine platform has changed history. For the first time, its clinical trials showed strong results in subjects. Almost all the individuals who were vaccinated a year ago showed boosted immune response in the latest clinical trial. For those who don’t know much about Vaxart, it is the biotechnology company that develops oral tablet vaccines.
For the first time, VXRT vaccinated the participants of the study in late 2019. The vaccination in these participants again happened between February and April 2021. Vaxart used an oral norovirus vaccine in this process.
Key Metrics:
- Serum antibody blocking titer 50 increased at a similar rate in both previously vaccinated and unvaccinated participants.
- The antibody that secrets B cell in response to norovirus VP1 were same for both previously vaccinated and unvaccinated subjects. These results reflect seven days post-boost measurements.
- responses of Serum IgG and IgA antibody showed significant elevation after 29 days of boost immunization. Titer was the same for both previously vaccinated and unvaccinated subjects.
VXRT stock’s license agreement with Altesa Biosciences:
On July 7, 2021, Vaxart stock signed the license agreement with Altesa Biosciences. Pursuant to the agreement, Vaxart had given its proprietary and patent-formulated VapendavirTM to Altesa for the development and commercialization. VapendavirTM is the antiviral that Vaxart stock has made to save millions of lives from viral infections.
Financial View of VXRT stock:
The earnings surprise history of Vaxart is not so much satisfactory. The stock has only beaten expectations once out of the trailing four quarters. The last quarter’s negative earnings surprise was 40%. One thing you need to know that Vaxart stock has no revenue resources other than royalty revenues.
Conclusion:
Investors are responding positively to the announcement of a positive clinical trial of the Vaxart oral vaccine platform. The upcoming financial results in August would further clarify the position of the Vaxart stock.
